Correlation between p65 and TNF-α in patients with acute myelocytic leukemia

Qiao-Mei Dong1, Chun Ling1, Jun-Fang Zhu1

  • 1Central Laboratory, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.

Oncology Letters
|January 2, 2016
PubMed

Insights

This study found that high levels of p65 and tumor necrosis factor-alpha (TNF-α) are common in acute myeloid leukemia (AML) patients and can help distinguish them from healthy individuals. These molecules also show a strong correlation, suggesting their potential as diagnostic and prognostic markers for AML.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Acute myeloid leukemia (AML) is a complex hematological malignancy.
  • Identifying reliable biomarkers for AML diagnosis and prognosis is crucial.

Purpose of the Study:

  • To investigate the correlation between p65 and tumor necrosis factor-alpha (TNF-α) expression in AML patients.
  • To evaluate their potential as diagnostic markers for distinguishing AML from non-leukemic samples.

Main Methods:

  • Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis were used to detect p65 and TNF-α.
  • Pearson's Correlation test and Receiver Operating Characteristic (ROC) curves were employed for statistical analysis.
  • Inhibition studies using MG132 and anti-TNF-α antibody were performed in the HL-60 cell line.

Main Results:

  • mRNA expression levels of p65 and TNF-α were significantly elevated in AML patients compared to controls.
  • A strong positive correlation was observed between p65 and TNF-α expression in AML bone marrow samples.
  • Inhibition of TNF-α reduced p65 expression, and inhibition of p65 reduced TNF-α expression in HL-60 cells.

Conclusions:

  • p65 and TNF-α are highly expressed and strongly correlated in AML patients.
  • These molecules demonstrate potential as diagnostic markers to differentiate AML from non-leukemic samples.
  • p65 and TNF-α may serve as valuable prognostic factors for AML patients.